Asset sale Announced

Gilead acquisition of HCXT-2001 (investigational oral IL-23R inhibitor)

Announced Oct 2026 (approx.)

Advisers

HCXT-2001 (investigational oral IL-23R inhibitor)

Target

Not disclosed

Gilead

Acquirer

Not disclosed

Other advisers

Financial adviser
Target
HCXT-2001 (investigational oral IL-23R inhibitor)
Acquirer
Gilead
Seller
PepStar Therapeutics
Target based in
China (unverified)
Buyer based in
United States
Seller based in
China (unverified)
Sector
Pharma
Tags
Pharma, Inflammation

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.